Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications

Biochem Biophys Res Commun. 2018 Sep 3;503(1):21-25. doi: 10.1016/j.bbrc.2018.04.156. Epub 2018 Jun 9.

Abstract

This study compared dipeptidyl peptidase-4 (DPP-4) inhibitory activity of citrus bioflavonoid nutraceuticals compared with three gliptins. Citrus bioflavonoid standards and three commercially available citrus bioflavonoid supplements (Thompson's Super Bioflavonoid Complex®(SB), Ethical Nutrients Bioflavonoids Plus Vitamin C®(EN), and Country Life Citrus Bioflavonoids and Rutin®(CB)) were considered in this study. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis was undertaken to identify and quantitate the citrus bioflavonoids present in each supplement. The DPP-4 inhibitory activity was determined by fluorometric assay. All of the tested individual citrus flavonoids demonstrated DPP-4 inhibitory activity, with IC50 values ranging from 485 μM (rutin) to 5700 μM (hesperitin and eriodictyol). Similarly, the flavonoid supplements had IC50 values of 16.9 mg/mL (EN), 3.44 mg/mL (SB) and 2.72 mg/mL (CB). These values compare with gliptin IC50 values of 0.684 μM (sitagliptin), 0.707 μM (saxagliptin) and 2.286 μM (vildagliptin). The supplement flavonoid content varied from 11.98% (CB) to 5.26% (EN) and 14.51% (SB) of tablet mass, corresponding to daily flavonoid doses of around 300, 150 and 400 mg, respectively, with CB and SB containing rutin at levels of 7.0% and 7.5% of tablet mass, respectively. While our data demonstrated that citrus bioflavonoid based supplements do possess DPP-4 inhibitory activity, they are several orders of magnitude less potent than gliptins. Further studies using higher concentrations of citrus bioflavonoids, as well as investigations into antioxidant properties which may add additional benefit are warranted.

Keywords: Citrus bioflavonoids; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitory assay; Gliptins; Ultra performance liquid chromatography.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adamantane / analogs & derivatives
  • Adamantane / chemistry
  • Adamantane / pharmacology
  • Citrus / chemistry*
  • Computer Simulation
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Dipeptides / chemistry
  • Dipeptides / pharmacology
  • Dipeptidyl Peptidase 4 / chemistry
  • Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
  • Dipeptidyl-Peptidase IV Inhibitors / chemistry*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
  • Flavonoids / administration & dosage
  • Flavonoids / chemistry*
  • Flavonoids / pharmacology*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / chemistry*
  • Hypoglycemic Agents / pharmacology*
  • In Vitro Techniques
  • Molecular Docking Simulation
  • Nitriles / chemistry
  • Nitriles / pharmacology
  • Pyrrolidines / chemistry
  • Pyrrolidines / pharmacology
  • Sitagliptin Phosphate / chemistry
  • Sitagliptin Phosphate / pharmacology
  • Spectrometry, Fluorescence
  • Tandem Mass Spectrometry
  • Vildagliptin

Substances

  • Dipeptides
  • Dipeptidyl-Peptidase IV Inhibitors
  • Flavonoids
  • Hypoglycemic Agents
  • Nitriles
  • Pyrrolidines
  • saxagliptin
  • Dipeptidyl Peptidase 4
  • Vildagliptin
  • Adamantane
  • Sitagliptin Phosphate